Bioo Scientific Partners with the Icahn School of Medicine at Mount Sinai
News Feb 14, 2015
Bioo Scientific has formed a partnership with the Icahn School of Medicine at Mount Sinai to bring to market randomized adapter technology to reduce ligation bias in NGS. Bioo Scientific has incorporated this patent pending technology into its NEXTflex™ Small RNA-Seq Library Prep Kit v2.
Ligation bias is reduced in libraries made using the NEXTflex Small RNA-Seq Library Prep Kit v2 and more accurate sequencing data is obtained. Previously published results (Jayaprakash, 2011) illustrate the utility of incorporating randomized adapters in small RNA library preparation in the dramatic reduction of ligation bias.
The approach utilized in the NEXTflex Small RNA-Seq Library Prep Kit v2 uses a pool of adapters containing randomized sequences at the ligation site. Because no single adapter sequence is able to efficiently ligate to all small RNAs, the target sequence, as well as the adapter sequence, is ordinarily a source of bias. This randomized adapter strategy allows small RNAs of any sequence to “find” their respective optimal adapters, resulting in small RNA libraries with a dramatic reduction in bias.
Ravi Sachidanandam, Assistant Professor of Oncological Sciences at the Icahn School of Medicine, who initially explored small RNA-Seq bias reduction using randomized adapters, states “Biases in sample prep are the bane of small RNA profiling through sequencing. We have shown that the T4-RNA ligases used in sample preparation are the predominant cause of bias as they mediate sequence-specific ligations. This bias can be ameliorated through the use of our randomized adapter technology. Through our partnership with Bioo Scientific we hope to make this technology available to all researchers interested in improving the accuracy of their small RNA-Seq analysis.”
According to Masoud Toloue, PhD., VP of Genomic Research for Bioo Scientific, “The NEXTflex Small RNA-Seq Library Prep Kit v2 is the only commercially available kit that incorporates this innovative randomized adapter technology to reduce ligation bias. The reduction of this bias is critical for increasing the accuracy of small RNA-Seq library preparation, specifically the differential expression of small RNAs.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.